Companies founded on innovation and strong science

Arxx Therapeutics

Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis.

The company leverages more than 30 years of research by its scientific co-founders

Sector: Biotechnology

Country: Norway/Denmark

Year of first investment: 2019

Status: Active

Website: arxxtx.com